イハラ　トシコ   Toshiko Ito-Ihara   猪原　登志子    所属   川崎医科大学  医学部 応用医学　先端医療開発学    職種   教授
論文種別	原著
言語種別	英語
査読の有無	査読あり
表題	Recombinant human FGF-2 therapy for osteonecrosis of the femoral head: 5-year follow-up.
掲載誌名	正式名：Regenerative medicine 略　 称：Regen Med ISSNコード：1746076X/17460751
掲載区分	国外
巻・号・頁	15(11),pp.2261-2271
著者・共著者	Yutaka Kuroda, Toshiko Ito-Ihara, Hiroyasu Abe, Manabu Nankaku, Yaichiro Okuzu, Toshiyuki Kawai, Koji Goto, Shuichi Matsuda
発行年月	2020/11
概要	Aim: To evaluate the 5-year outcomes from the prospective study of recombinant human FGF-2 (rhFGF-2) for osteonecrosis of the femoral head (ONFH). Methods: Ten patients (average age 39.8 years) with nontraumatic, precollapse ONFH were percutaneously administered with 800 μg rhFGF-2 contained in gelatin hydrogel. Radiological changes and the prevalidated Harris hip score (HHS), visual analogue scale for pain and University of California, Los Angeles activity-rating scale scoring systems were evaluated. Results: The 5-year comparison in type C2 showed higher joint preservation in the rhFGF-2 group (71.4%) than in the natural course group (15.4%). Two of three clinical scores (Harris hip score and visual analogue scale for pain) improved significantly. Postoperative MRI demonstrated significant reduction in ONFH size. There were no adverse events. Conclusion: rhFGF-2 treatment for ONFH appears to be safe and effective and may have the potential to prevent disease progression.
DOI	10.2217/rme-2020-0148
PMID	33256551